|
Leukemia, Myelocytic, Acute
|
0.200 |
GeneticVariation
|
disease |
BEFREE |
Mutations in SRSF2 gene are frequently reported in myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML).
|
31040863 |
2019 |
|
Leukemia, Myelocytic, Acute
|
0.200 |
Biomarker
|
disease |
BEFREE |
AML transformation occurred faster in SMF than in PMF and patients who transformed to AML were more SRSF2-mutated and less CALR-mutated at MF sampling.
|
31340059 |
2019 |
|
Leukemia, Myelocytic, Acute
|
0.200 |
Biomarker
|
disease |
BEFREE |
Patients with additional mutation at first sample showed a higher probability of developing cytopenia under HU therapy and a higher risk of AML (HR 12.2, 95% CI 2.6-57.1, p = 0.001) with mutations in ASXL1 (p < 0.0001), TP53 (p = 0.01), SRSF2 (p < 0.0001), IDH1/2 (p < 0.0001), and RUNX1 (p < 0.0001) being associated with a higher probability of AML.
|
29181548 |
2018 |
|
Leukemia, Myelocytic, Acute
|
0.200 |
GeneticVariation
|
disease |
BEFREE |
This meta-analysis indicates an independent, adverse prognostic impact of SRSF2 mutations on OS and AML transformation in patients with de novo MDS.
|
28953917 |
2017 |
|
Leukemia, Myelocytic, Acute
|
0.200 |
GeneticVariation
|
disease |
BEFREE |
These results suggest that SRSF2 mutation occurs at a low frequency in aged AML patients and might not be associated with adverse prognosis in Chinese AML patients.
|
26820131 |
2016 |
|
Leukemia, Myelocytic, Acute
|
0.200 |
GeneticVariation
|
disease |
BEFREE |
To test this hypothesis, we engineered mice to express a mutated allele of serine/arginine-rich splicing factor 2 (Srsf2(P95H))-which commonly occurs in individuals with MDS and AML-in an inducible, hemizygous manner in hematopoietic cells.
|
27135740 |
2016 |
|
Leukemia, Myelocytic, Acute
|
0.200 |
GeneticVariation
|
disease |
BEFREE |
The SRSF2 mutation was somewhat associated with AML transformation (P = 0.083).
|
26115659 |
2015 |
|
Leukemia, Myelocytic, Acute
|
0.200 |
GeneticVariation
|
disease |
BEFREE |
Over the past few years, large-scale genomic studies of patients with myelodysplastic syndrome (MDS) and acute myelogenous leukemia (AML) have unveiled recurrent somatic mutations in genes involved in epigenetic regulation (DNMT3A, IDH1/2, TET2, ASXL1, EZH2 and MLL) and the spliceosomal machinery (SF3B1, U2AF1, SRSF2, ZRSR2, SF3A1, PRPF40B, U2AF2, and SF1).
|
23645565 |
2013 |
|
Leukemia, Myelocytic, Acute
|
0.200 |
GeneticVariation
|
disease |
BEFREE |
SRSF2 mutations are more common in AML derived from MPNs compared with LT after myelodysplasia (4.8%) or de novo AML (5.6%), respectively (P=.05).
|
22431577 |
2012 |
|
Leukemia, Myelocytic, Acute
|
0.200 |
GeneticVariation
|
disease |
BEFREE |
Nuclear proteins that are localized in discrete domains within the nucleus include the leukemia-associated acute myelogenous leukemia (AML) and promyelocytic leukemia (PML) factors, the SC-35 RNA-processing factors, nucleolar proteins and components of both transcriptional and DNA replication complexes.
|
10862710 |
2000 |
|
Leukemia, Myelocytic, Acute
|
0.200 |
Biomarker
|
disease |
HPO |
|
|
|